Edesa Biotech, Inc. Common Shares (EDSA)
PHARMACEUTICAL PREPARATIONS
Edesa Biotech, Inc. Common Shares (EDSA) is listed on Nasdaq, where it has traded since June 9, 2010.
- Listed On
- Nasdaq
- Listed Since
- June 9, 2010
- Employees
- 17
- Market Cap
- $34M
About Edesa Biotech, Inc. Common Shares
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 31 institutions reported holding EDSA, with 3.8 million shares worth $31.0 million in aggregate. The largest reported holder was Velan Capital Investment Management, with 827,500 shares worth $6.7 million. Of the 5 largest holders listed below, 1 opened a new position in EDSA, 1 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Velan Capital Investment Management | 827,500 | $7M | Unchanged |
| Rubric Capital Management | 669,500 | $5M | Reduced 2.62% |
| Perceptive Advisors | 563,239 | $5M | Unchanged |
| Millennium Management | 561,751 | $5M | New position |
| Stonepine Capital Management | 456,439 | $3M | Added 1421.46% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is EDSA?
Edesa Biotech, Inc. Common Shares (EDSA) is listed on Nasdaq, where it has traded since June 9, 2010.
Who are the largest institutional holders of EDSA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of EDSA were Velan Capital Investment Management, Rubric Capital Management and Perceptive Advisors.
How many institutions own EDSA?
31 institutions reported a position in EDSA for the quarter ended June 30, 2026, worth $31.0 million in total.
Did institutions buy or sell EDSA last quarter?
Of the 5 largest reported holders, 1 opened a new position in EDSA, 1 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for EDSA.
Every reported institutional holder, plus insider and congressional trades in EDSA, on SentiSense.